Sipai Health Technology (0314) H1 2023 earnings summary

Executive summary

• H1 revenue rose 29.2% YoY to RMB2,437.96m; IFRS net loss narrowed to RMB87.31m from RMB345.99m.

• Adjusted net loss fell to RMB33.19m from RMB143.11m, excluding preferred-share fair-value changes, share-based compensation and listing expenses.

• Priorities remained organic growth, operational efficiency, digitalization and business synergies.

Financial highlights

• Gross profit rose 23.3% to RMB218.09m; gross margin declined to 8.9% from 9.4%.

• Loss attributable to ordinary equity holders narrowed to RMB92.32m from RMB346.33m; basic and diluted loss per share was RMB0.14 versus RMB3.50.

• Selling and marketing expenses were RMB152.05m, down 5.3%; administrative expenses were RMB175.38m, down 30.5%; R&D expenses were RMB23.86m, down 30.4%.

• Other income and gains rose to RMB52.30m from RMB22.35m, including government grants of RMB23.22m and interest income of RMB19.76m.

Outlook and guidance

• Priorities include organic growth, operational efficiency, continued digitalization and synergy development; no quantified financial guidance was stated.

• Future operating cash generation is expected as commercialized product sales grow; liquidity needs are expected to be funded by cash and Global Offering proceeds.

• The “health insurance plus healthcare management” model aims to expand customer reach while supporting preventive care and management of healthcare expenditure.